Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma

Journal of Surgical Oncology

Volumn 109, Issue 4, 2014, Pages 314-319

  Ross, Merrick I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

intralesional therapy; melanoma; treatment

Indexed keywords

INTRALESIONAL THERAPY; MELANOMA; TREATMENT;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; INJECTIONS, INTRALESIONAL; MELANOMA; MULTICENTER STUDIES AS TOPIC; NEOPLASM METASTASIS; ROSE BENGAL;

EID: 84893939194     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23554     Document Type: Review

References (19)

1. Gershenwald JE, Ross MI,: Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med 2011; 364: 1738-1745.
2. Balch CM, Gershenwald JE, Soong SJ, et al.: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
3. Page DB, Postow MA, Callahan MK, et al.: Immune modulation in cancer with antibodies. Ann Rev Med 2014; 65: 185-202.
4. Salama AK, Flahery KT,: BRAF in melanoma: Current strategies and future directions. Clin Cancer Res 2013; 19: 4326-4334.
5. Salama AK, Kim KB,: MEK inhibition in the treatment of advanced melanoma. Curr Oncol Rep 2013; 15: 473-482.
6. Gimbel MI, Delman KA, Zager JS,: Therapy for unresectable, recurrent and in-transit extremity melanoma. Cancer Control 2008; 15: 225-232.
7. Testori A, Faries MB, Thompson JF, et al.: Local and intralesional therapy of in-transit mel. J Surg Oncol 2011; 104: 391-396.
8. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology, melanoma, version 2. 2014
9. Senzer NN, Kaufman HL, Amatruda T, et al.: Phase II clinical trial of a granulocyte- macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763-5771.
10. Gonzalez R, Hutchins L, Nemunaitis J, et al.: Phase 2 trial of Allovectin-7 in advanced metastatic mel. Melanoma Res 2006; 16: 521-526.
11. Thompson JF, Hersey P, Wachter E,: Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 2008; 18: 405-411.
12. Kubin RH, Grodsky GM, Carbone JV,: Investigation of rose bengal conjugation. Proc Soc Exp Biol Med 1960; 104: 650-653.
13. Pirotte J,: Suitability criteria for compartmental analysis of the plasma clearance curve of exogenous cholephils. 1311 rose bengal fulfills these criteria. Biomedicine 1979; 30: 211-215.
14. Delprat GD, Epstein NN, Kerr WJ,: A new liver function test. The elimination of rose bengal when injected into the circulation of human subjects. Arch Intern Med 1924; 34: 533-541.
15. Marsh RJ, Fraunfelder FT, McGill JI, et al.: Herpetic corneal epithelial. Arch Ophthalmol 1976; 94: 1899-1902.
16. Wachter E, Dees C, Harkins J, et al.: Imaging photosensitizer distribution and pharmacology using multiphoton microscopy. In:, Farkas DL, Leif RC, editors, Proceedings of SPIE, optical diagnostics of living cells V, Vol. 4622. Washington: Bellingham; 2002. pp. 112-118.
17. Mousavi H, Zhang X, Gillespie S, et al.: Rose bengal induces dual modes of cell death in melanoma cells and has clinical activity against melanoma. Melanoma Res 2006; 16: S8.
18. Foote MC, Burmeister BH, Thomas J, et al.: A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: A case series. Melanoma Res 2010; 20: 48-51.
19. Toomey P, Kodumudi K, Weber A, et al.: Intralesional injection of rose bengal induces a tumor-specific immune response in murine models of melonama and breast cancer. PLoS ONE 2013; 8: e68561.